CD-MEDICS

The overall concept of the CD-MEDICS IP is to develop a technology platform for point-of-care diagnostics, capable of simultaneous genomic and proteomic detection, with embedded communication abilities for direct interfacing with hospital information systems. This will be achieved by exploiting breakthroughs at the confluences of bio-, micro- and nano- technologies to create a low-cost non-invasive intelligent diagnosis system.

This platform will be developed in a modular format, which will allow each module to be developed and exploited individually. The modules will subsequently be integrated to facilitate the desired application. Advances in data communications, molecular biology and biosensor technology, with the integration of nanostructured functional components in macro and microsystems, will facilitate the realisation of a minimally invasive generic platform, which is capable of multi-parametric monitoring and will be interoperable with electronic medical records.

The advantages of integrated biosensor systems include their ease of use, their sensitivity, their inherent selectivity (preventing problems due to interfering substances), their versatility (allowing `in-field¿ use) and their cost effectiveness. Addressing the future health care requirement of an individualised theranostic approach, the specific application that will be demonstrated in this IP will be for the management, monitoring and diagnosis of coeliac disease, with the proposed technology contributing to significant advances in sensitivity and specificity of diagnosis. The technology platform developed, however, could be applied to a variety of clinical screening applications, such as cancer. The radical innovation proposed in this IP will result in a concrete prime deliverable of a technology platform of wide application and unquestionable socio-economic benefit, increasing European competitiveness whilst contributing considerably to the quality of life well being of the population.

For further information, please visit:
http://www.cdmedics.eu

Project co-ordinator:
Universitat Rovira i Virgili

Partners:

  • Institut für Mikrotechnik Mainz GmbH
  • Microfluidic ChipShop GmbH
  • Newcastle University
  • Intracom Telecom solutions
  • Clemens GmbH
  • Micro2Gen
  • Eurospital SpA
  • King's College London Business Ltd
  • INNO-TRAIN Diagnostik GmbH
  • TATAA Biocenter
  • MultiD Analyses AB
  • Finnish Red Cross Blood Service
  • Fondazione IRCCS Policlinico San Matteo
  • University Medical Centre Maribor
  • Valentia Technologies Limited
  • Association of European Coeliac Societies
  • Coeliac UK
  • Asociación de celíacos de Madrid
  • iXscient Ltd.
  • Newcastle upon Tyne Hospitals NHS Foundation Trust

Timetable: from 01/2008 – to 12/2011

Total cost: € 12.796.559

EC funding: € 9.500.000

Programme Acronym: FP7-ICT

Subprogramme Area: Personal health systems for monitoring and point-of-care diagnostics

Contract type: Collaborative project (generic)


Related news article:

Most Popular Now

Open Call HORIZON-HLTH-2021-TOOL-06-03: …

This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination 5 "Unlocking the full potential of new tools, technologies and digital...

CSAM Acquires Optima - Further Boosts eH…

CSAM Health Group AS ("CSAM"), the leading provider of niche eHealth solutions in the Nordics, today announced it has signed a deal to acquire eHealth player Optima Corporation Ltd from...

Novartis and Hewlett Packard Enterprise …

Novartis and Hewlett Packard Enterprise (HPE)announced a collaboration that aims to accelerate the use of data and digital technologies within Novartis efforts to reimagine global health and improve access to...

COVID-19 Origins Still a Mystery

Scientists using computer modelling to study SARS-CoV-2, the virus that caused the COVID-19 pandemic, have discovered the virus is most ideally adapted to infect human cells - rather than bat...

Using Artificial Intelligence to Overcom…

Depression is a worldwide problem, with serious consequences for individual health and the economy, and rapid and effective screening tools are thus urgently needed to counteract its increasing prevalence. Now...

Deep Machine Learning Completes Informat…

The Structural Bioinformatics and Network Biology laboratory, led by ICREA Researcher Dr. Patrick Aloy, has completed the bioactivity information for a million molecules using deep machine-learning computational models. It has...

EU Digital COVID Certificate Enters into…

The EU Digital COVID Certificate Regulation enters into application. This means that EU citizens and residents will now be able to have their Digital COVID Certificates issued and verified across...

Philips and the Spanish National Center …

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, has participated in an important research project to develop a magnetic resonance (MR) imaging technique [1,2] that could...

Scottish Health and Care Professionals G…

Scottish health and care professionals across a wide range of clinical settings including NHS Scotland health boards are being given access to an individual's COVID-19 vaccine status through the Orion...

Ethics and Governance of Artificial Inte…

Artificial Intelligence (AI) refers to the ability of algorithms encoded in technology to learn from data so that they can perform automated tasks without every step in the process having...

It's Going to be Quite a Handover…

Health and social care secretary Matt Hancock has been abruptly replaced by Sajid Javid. The Highland Marketing advisory board consider the huge agenda he is now facing, and what it...

Philips Accelerates Stroke Diagnosis and…

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced a strategic partnership agreement with NICO.LAB, a MedTech stroke care company. Together with the recently expanded stroke...